Customer Center
Login | Register

Clinical

Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, including infectious disease testing, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.

Read More

Research & Applied Markets

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.


Read More

 

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® Technology. Click here to start the conversation now.


Learn More

 

Luminex® Blog

Choosing an MDx Platform

Important factors to consider for meeting a community’s infectious disease needs

Recently, clinical laboratories have seen a dramatic increase in the adoption of molecular diagnostic systems for infectious disease testing. These platforms support a laboratory’s need to generate clinically actionable data faster than ever before, compared to traditional methods, without compromising reliable performance…

Continue Reading…

Galapagos, A Luminex Partner

 
Galapagos, A Luminex Partner

 

The team from Galapagos NV talks about their Mission to become the largest Biotech company in Europe, and how automating the Luminex FLEXMAP 3D® system is helping with their drug discovery.

Watch more videos >

Luminex on Twitter


The Luminex family wouldn't look the same without the efforts of Jennifer Hackel: https://t.co/08amxiGlRGhttps://t.co/LKAksOF0dH
h J R
Consider these factors when selecting the right #moleculardiagnostic platform for your patient population:… https://t.co/AbARMWTnLF
h J R
Learn about the many applications of multiplex #immunoassays and how to overcome any challenges:… https://t.co/m2EspxTVp1
h J R

Latest News

August 29
Luminex Corporation and Sutter Health Collaborate to Improve Patient Care

August 7
Luminex Corporation Reports Second Quarter 2017 Financial Results

July 24
Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay

July 17
Luminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2017

June 28
Luminex Corporation Receives CE-IVD Mark for ARIES® Norovirus Assay

June 5
Luminex Corporation’s VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan

Events

SWACM Annual Meeting
September 6-9
St. Louis, MO

xMAP Connect U.S. 2017
September 19
Boston, MA

Intermountain States Seminar
September 29-30
Jackson, WY

PSI Annual Meeting
October 3
Dublin, OH

IDWeek
October 4-8
San Diego, CA